{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:58:33Z","timestamp":1793048313691,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03012-9","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:58:25Z","timestamp":1756738705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting Nrf2 in acute myeloid leukemia: an updated review on its role in chemoresistance and emerging therapeutic strategies"],"prefix":"10.1007","volume":"42","author":[{"given":"Deepthi Maria","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abilash Valsala","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"5","key":"3012_CR1","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.18632\/oncotarget.13825","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang J, et al. Discovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells, (in eng). Oncotarget. 2017;8(5):7625\u201336. https:\/\/doi.org\/10.18632\/oncotarget.13825.","journal-title":"Oncotarget"},{"key":"3012_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005.","journal-title":"Blood Rev"},{"key":"3012_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023. https:\/\/doi.org\/10.1186\/s13045-023-01424-6.","journal-title":"J Hematol Oncol"},{"key":"3012_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134777","author":"F He","year":"2020","unstructured":"He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21134777.","journal-title":"Int J Mol Sci"},{"key":"3012_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25225474","author":"S Saha","year":"2020","unstructured":"Saha S, Buttari B, Panieri E, Profumo E, Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25225474.","journal-title":"Molecules"},{"issue":"9","key":"3012_CR6","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.3390\/ijms22094642","volume":"22","author":"CA Juan","year":"2021","unstructured":"Juan CA, P\u00e9rez de la Lastra JM, Plou FJ, P\u00e9rez-Lebe\u00f1a E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci. 2021;22(9):4642.\u00a010.3390\/ijms22094642","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3012_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.tibs.2010.04.002","volume":"35","author":"RB Hamanaka","year":"2010","unstructured":"Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes, (in eng). Trends Biochem Sci. 2010;35(9):505\u201313. https:\/\/doi.org\/10.1016\/j.tibs.2010.04.002.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"3012_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-023-00411-4","volume":"12","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis. Exp Hematol Oncol. 2023;12(1):47.https:\/\/doi.org\/10.1186\/s40164-023-00411-4","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"3012_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ng.3126","volume":"46","author":"Y Totoki","year":"2014","unstructured":"Totoki Y, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, (in eng). Nat Genet. 2014;46(12):1267\u201373. https:\/\/doi.org\/10.1038\/ng.3126.","journal-title":"Nat Genet"},{"issue":"1","key":"3012_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer,. Cancer Cell. 2018;34(1):21\u201343. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.022.","journal-title":"Cancer Cell"},{"issue":"14","key":"3012_CR11","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1074\/jbc.M709040200","volume":"283","author":"M Theodore","year":"2008","unstructured":"Theodore M, et al. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem. 2008;283(14):8984\u201394. https:\/\/doi.org\/10.1074\/jbc.M709040200.","journal-title":"J Biol Chem"},{"issue":"4","key":"3012_CR12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1074\/jbc.M209195200","volume":"278","author":"D Stewart","year":"2003","unstructured":"Stewart D, Killeen E, Naquin R, Alam S, Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium, (in eng). J Biol Chem. 2003;278(4):2396\u2013402. https:\/\/doi.org\/10.1074\/jbc.M209195200.","journal-title":"J Biol Chem"},{"key":"3012_CR13","doi-asserted-by":"publisher","first-page":"2746457","DOI":"10.1155\/2016\/2746457","volume":"2016","author":"J Kim","year":"2016","unstructured":"Kim J, Keum YS. NRF2, a key regulator of antioxidants with two faces towards cancer, (in eng). Oxid Med Cell Longev. 2016;2016:2746457. https:\/\/doi.org\/10.1155\/2016\/2746457.","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"3012_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jphs.2014.12.010","volume":"127","author":"M Lin","year":"2015","unstructured":"Lin M, et al. Salvianolic acid B protects against acetaminophen hepatotoxicity by inducing Nrf2 and phase II detoxification gene expression via activation of the PI3K and PKC signaling pathways, (in eng). J Pharmacol Sci. 2015;127(2):203\u201310. https:\/\/doi.org\/10.1016\/j.jphs.2014.12.010.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"3012_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s42003-021-02100-6","volume":"4","author":"Y Horie","year":"2021","unstructured":"Horie Y, et al. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge and Latch mechanism, (in eng). Commun Biol. 2021;4(1):576. https:\/\/doi.org\/10.1038\/s42003-021-02100-6.","journal-title":"Commun Biol"},{"key":"3012_CR16","doi-asserted-by":"crossref","unstructured":"W. Fu et al., Neh1 and Neh3 domains of nuclear factor erythroid 2-related factor 2 mediate its binding to NAD-dependent protein deacetylase sirtuin-6, 2022.","DOI":"10.21203\/rs.3.rs-1552407\/v1"},{"issue":"10","key":"3012_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1046\/j.1365-2443.2001.00469.x","volume":"6","author":"Y Katoh","year":"2001","unstructured":"Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells. 2001;6(10):857\u201368. https:\/\/doi.org\/10.1046\/j.1365-2443.2001.00469.x.","journal-title":"Genes Cells"},{"issue":"4","key":"3012_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.15430\/jcp.2023.28.4.131","volume":"28","author":"HKC Ngo","year":"2023","unstructured":"Ngo HKC, Le H, Surh YJ. Nrf2, A target for precision oncology in cancer prognosis and treatment, (in eng). J Cancer Prev. 2023;28(4):131\u201342. https:\/\/doi.org\/10.15430\/jcp.2023.28.4.131.","journal-title":"J Cancer Prev"},{"issue":"34","key":"3012_CR19","doi-asserted-by":"publisher","first-page":"30091","DOI":"10.1074\/jbc.M501279200","volume":"280","author":"DD Zhang","year":"2005","unstructured":"Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway, (in eng). J Biol Chem. 2005;280(34):30091\u20139. https:\/\/doi.org\/10.1074\/jbc.M501279200.","journal-title":"J Biol Chem"},{"key":"3012_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.freeradbiomed.2022.09.023","volume":"192","author":"R Srivastava","year":"2022","unstructured":"Srivastava R, Fern\u00e1ndez-Gin\u00e9s R, Encinar JA, Cuadrado A, Wells G. The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and \u03b2-TrCP-NRF2 interactions in cancer chemoresistance. Free Radic Biol Med. 2022;192:24660.https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.09.023","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3012_CR21","doi-asserted-by":"publisher","first-page":"8592348","DOI":"10.1155\/2019\/8592348","volume":"2019","author":"E Panieri","year":"2019","unstructured":"Panieri E, Saso L. Potential applications of NRF2 inhibitors in cancer therapy. Oxid Med Cell Longev. 2019;https:\/\/doi.org\/10.1155\/2019\/8592348","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"3012_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030740","volume":"12","author":"W Chauhan","year":"2023","unstructured":"Chauhan W, Zennadi R. Keap1-Nrf2 heterodimer: a therapeutic target to ameliorate sickle cell disease. Antioxidants. 2023;12(3):740.https:\/\/doi.org\/10.3390\/antiox12030740","journal-title":"Antioxidants"},{"issue":"3","key":"3012_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.bbrc.2014.08.111","volume":"452","author":"J Wu","year":"2014","unstructured":"Wu J, Wang H, Tang X. Rexinoid inhibits Nrf2-mediated transcription through retinoid X receptor alpha, (in eng). Biochem Biophys Res Commun. 2014;452(3):554\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2014.08.111.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"3012_CR24","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/0008-5472.Can-12-3386","volume":"73","author":"H Wang","year":"2013","unstructured":"Wang H, et al. RXR\u03b1 inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2, . Cancer Res. 2013;73(10):3097\u2013108. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-3386.","journal-title":"Cancer Res"},{"issue":"6","key":"3012_CR25","doi-asserted-by":"publisher","first-page":"200105","DOI":"10.1098\/rsob.200105","volume":"10","author":"S Dayalan Naidu","year":"2020","unstructured":"Dayalan Naidu S, Dinkova-Kostova AT. KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease, . Open Biol. 2020;10(6):200105. https:\/\/doi.org\/10.1098\/rsob.200105.","journal-title":"Open Biol"},{"issue":"5","key":"3012_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00044-020-02539-y","volume":"29","author":"S Lee","year":"2020","unstructured":"Lee S, Hu L. Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction, (in eng). Med Chem Res. 2020;29(5):846\u201367. https:\/\/doi.org\/10.1007\/s00044-020-02539-y.","journal-title":"Med Chem Res"},{"key":"3012_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Q Ma","year":"2013","unstructured":"Ma Q. Role of nrf2 in oxidative stress and toxicity, (in eng). Annu Rev Pharmacol Toxicol. 2013;53:401\u201326. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140320.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"3012_CR28","first-page":"454659","volume":"2015","author":"A Abdul-Aziz","year":"2015","unstructured":"Abdul-Aziz A, MacEwan DJ, Bowles KM, Rushworth SA. Oxidative stress responses and NRF2 in human leukaemia. Oxid Med Cell Longev. 2015;2015(1):454659.https:\/\/doi.org\/10.1155\/2015\/454659","journal-title":"Oxid Med Cell Longev"},{"key":"3012_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.freeradbiomed.2014.11.009","volume":"79","author":"EJ Moon","year":"2015","unstructured":"Moon EJ, Giaccia A. \u201cDual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment,\u201d (in eng). Free Radic Biol Med. 2015;79:292\u20139. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.11.009.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3012_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-024-01487-0","volume":"44","author":"S Davinelli","year":"2024","unstructured":"Davinelli S, Medoro A, Savino R, Scapagnini G. Sleep and oxidative stress: current perspectives on the role of NRF2. Cell Mol Neurobiol. 2024;44(1):52.https:\/\/doi.org\/10.1007\/s10571-024-01487-0","journal-title":"Cell Mol Neurobiol"},{"key":"3012_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123056","author":"AA Bhat","year":"2024","unstructured":"Bhat AA, et al. Nrf2 pathways in neuroprotection: alleviating mitochondrial dysfunction and cognitive impairment in aging. Life Sci. 2024. https:\/\/doi.org\/10.1016\/j.lfs.2024.123056.","journal-title":"Life Sci"},{"issue":"4","key":"3012_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","volume":"39","author":"JD Hayes","year":"2014","unstructured":"Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39(4):199\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2014.02.002.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"3012_CR33","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/cam4.2101","volume":"8","author":"S Wu","year":"2019","unstructured":"Wu S, Lu H, Bai Y. Nrf2 in cancers: a double-edged sword, (in eng). Cancer Med. 2019;8(5):2252\u201367. https:\/\/doi.org\/10.1002\/cam4.2101.","journal-title":"Cancer Med"},{"issue":"6","key":"3012_CR34","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1073\/pnas.051618798","volume":"98","author":"M Ramos-Gomez","year":"2001","unstructured":"Ramos-Gomez M, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice, (in eng). Proc Natl Acad Sci U S A. 2001;98(6):3410\u20135. https:\/\/doi.org\/10.1073\/pnas.051618798.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"3012_CR35","doi-asserted-by":"publisher","first-page":"12731","DOI":"10.1073\/pnas.96.22.12731","volume":"96","author":"K Chan","year":"1999","unstructured":"Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice, (in eng). Proc Natl Acad Sci U S A. 1999;96(22):12731\u20136. https:\/\/doi.org\/10.1073\/pnas.96.22.12731.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3012_CR36","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1073\/pnas.081082098","volume":"98","author":"K Chan","year":"2001","unstructured":"Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen, (in eng). Proc Natl Acad Sci U S A. 2001;98(8):4611\u20136. https:\/\/doi.org\/10.1073\/pnas.081082098.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3012_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.20121337","volume":"210","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival, (in eng). J Exp Med. 2013;210(8):1529\u201344. https:\/\/doi.org\/10.1084\/jem.20121337.","journal-title":"J Exp Med"},{"key":"3012_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/763257","volume":"2013","author":"SM Shin","year":"2013","unstructured":"Shin SM, Yang JH, Ki SH. Role of the Nrf2-ARE pathway in liver diseases, (in eng). Oxid Med Cell Longev. 2013;2013:763257. https:\/\/doi.org\/10.1155\/2013\/763257.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"3012_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/carcin\/bgaa039","volume":"41","author":"F He","year":"2020","unstructured":"He F, Antonucci L, Karin M. NRF2 as a regulator of cell metabolism and inflammation in cancer, (in eng). Carcinogenesis. 2020;41(4):405\u201316. https:\/\/doi.org\/10.1093\/carcin\/bgaa039.","journal-title":"Carcinogenesis"},{"issue":"11","key":"3012_CR40","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.4049\/jimmunol.0804248","volume":"182","author":"NM Reddy","year":"2009","unstructured":"Reddy NM, Kleeberger SR, Kensler TW, Yamamoto M, Hassoun PM, Reddy SP. Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice, (in eng). J Immunol. 2009;182(11):7264\u201371. https:\/\/doi.org\/10.4049\/jimmunol.0804248.","journal-title":"J Immunol"},{"issue":"5","key":"3012_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age, (in eng). Nat Rev Immunol. 2018;18(5):309\u201324. https:\/\/doi.org\/10.1038\/nri.2017.142.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"3012_CR42","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuro.2006.07.019","volume":"27","author":"NC Burton","year":"2006","unstructured":"Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2, (in eng). Neurotoxicology. 2006;27(6):1094\u2013100. https:\/\/doi.org\/10.1016\/j.neuro.2006.07.019.","journal-title":"Neurotoxicology"},{"key":"3012_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03331-x","author":"P Liu","year":"2021","unstructured":"Liu P, Ma D, Wang P, Pan C, Fang Q, Wang J. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death Dis. 2021. https:\/\/doi.org\/10.1038\/s41419-020-03331-x.","journal-title":"Cell Death Dis"},{"issue":"18","key":"3012_CR44","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/0008-5472.Can-04-1906","volume":"64","author":"K Iida","year":"2004","unstructured":"Iida K, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis, (in eng). Cancer Res. 2004;64(18):6424\u201331. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-1906.","journal-title":"Cancer Res"},{"issue":"1","key":"3012_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.Cd-16-0127","volume":"7","author":"Y Jeong","year":"2017","unstructured":"Jeong Y, et al. Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance, (in eng). Cancer Discov. 2017;7(1):86\u2013101. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0127.","journal-title":"Cancer Discov"},{"key":"3012_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081879","author":"M S\u00e1nchez-Ortega","year":"2021","unstructured":"S\u00e1nchez-Ortega M, Carrera AC, Garrido A. Role of NRF2 in lung cancer. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081879.","journal-title":"Cells"},{"issue":"1","key":"3012_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41389-024-00536-z","volume":"13","author":"X Jin","year":"2024","unstructured":"Jin X, et al. NRF2 signaling plays an essential role in cancer progression through the NRF2-GPX2-NOTCH3 axis in head and neck squamous cell carcinoma. Oncogenesis. 2024;13(1):35.https:\/\/doi.org\/10.1038\/s41389-024-00536-z","journal-title":"Oncogenesis"},{"issue":"1","key":"3012_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41389-024-00536-z","volume":"13","author":"X Jin","year":"2024","unstructured":"Jin X, et al. NRF2 signaling plays an essential role in cancer progression through the NRF2-GPX2-NOTCH3 axis in head and neck squamous cell carcinoma, (in eng). Oncogenesis. 2024;13(1):35. https:\/\/doi.org\/10.1038\/s41389-024-00536-z.","journal-title":"Oncogenesis"},{"issue":"4","key":"3012_CR49","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s42255-020-0191-z","volume":"2","author":"DB Fox","year":"2020","unstructured":"Fox DB, et al. NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism, (in eng). Nat Metab. 2020;2(4):318\u201334. https:\/\/doi.org\/10.1038\/s42255-020-0191-z.","journal-title":"Nat Metab"},{"issue":"2","key":"3012_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","volume":"16","author":"K Taguchi","year":"2011","unstructured":"Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1\u2013Nrf2 pathway in stress response and cancer evolution, (in eng). Genes Cells. 2011;16(2):123\u201340. https:\/\/doi.org\/10.1111\/j.1365-2443.2010.01473.x.","journal-title":"Genes Cells"},{"issue":"13","key":"3012_CR51","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1074\/jbc.M111.312694","volume":"287","author":"SK Niture","year":"2012","unstructured":"Niture SK, Jaiswal AK. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012;287(13):9873\u201386. https:\/\/doi.org\/10.1074\/jbc.M111.312694.","journal-title":"J Biol Chem"},{"key":"3012_CR52","doi-asserted-by":"publisher","first-page":"1184079","DOI":"10.3389\/fonc.2023.1184079","volume":"13","author":"L Lin","year":"2023","unstructured":"Lin L, et al. Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers, (in eng). Front Oncol. 2023;13:1184079. https:\/\/doi.org\/10.3389\/fonc.2023.1184079.","journal-title":"Front Oncol"},{"key":"3012_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0050-0","author":"I Nepstad","year":"2019","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Aaseb\u00f8 E, Hernandez-Valladares M, Hagen KM, et al. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct Target Ther. 2019. https:\/\/doi.org\/10.1038\/s41392-019-0050-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"3012_CR54","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","volume":"21","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells.\u00a0International journal of molecular sciences, vol. 21, no. 8, p. 2907,  2020;21(8):2907.https:\/\/doi.org\/10.3390\/ijms21082907","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3012_CR55","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Yang X, Geng M, Huang M. Targeting ERK, an achilles\u2019 heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8(4):552\u201362. https:\/\/doi.org\/10.1016\/j.apsb.2018.01.008.","journal-title":"Acta Pharm Sin B"},{"key":"3012_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fonc.2018.00160","volume":"8","author":"N Koundouros","year":"2018","unstructured":"Koundouros N, Poulogiannis G. Phosphoinositide 3-kinase\/Akt signaling and redox metabolism in cancer. Front Oncol. 2018;8:160.10.3389\/fonc.2018.00160","journal-title":"Front Oncol"},{"issue":"1","key":"3012_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","volume":"22","author":"Y Mitsuishi","year":"2012","unstructured":"Mitsuishi Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22(1):66\u201379.","journal-title":"Cancer Cell"},{"issue":"1","key":"3012_CR58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease, (in eng). Cell. 2017;170(1):17\u201333. https:\/\/doi.org\/10.1016\/j.cell.2017.06.009.","journal-title":"Cell"},{"issue":"1","key":"3012_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1535-7163.MCT-24-0504","volume":"24","author":"Y Chen","year":"2025","unstructured":"Chen Y, Yin Z, Westover KD, Zhou Z, Shu L. Advances and challenges in RAS signaling targeted therapy in leukemia. Mol Cancer Ther. 2025;24(1):33\u201346.https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0504","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"3012_CR60","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web, (in eng). Nat Rev Cancer. 2011;11(11):761\u201374. https:\/\/doi.org\/10.1038\/nrc3106.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3012_CR61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ncb2021","volume":"12","author":"M Komatsu","year":"2010","unstructured":"Komatsu M, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1, (in eng). Nat Cell Biol. 2010;12(3):213\u201323. https:\/\/doi.org\/10.1038\/ncb2021.","journal-title":"Nat Cell Biol"},{"issue":"13","key":"3012_CR62","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1128\/mcb.00248-10","volume":"30","author":"A Lau","year":"2010","unstructured":"Lau A, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62, (in eng). Mol Cell Biol. 2010;30(13):3275\u201385. https:\/\/doi.org\/10.1128\/mcb.00248-10.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"3012_CR63","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.molcel.2013.08.003","volume":"51","author":"Y Ichimura","year":"2013","unstructured":"Ichimura Y, et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy, (in eng). Mol Cell. 2013;51(5):618\u201331. https:\/\/doi.org\/10.1016\/j.molcel.2013.08.003.","journal-title":"Mol Cell"},{"issue":"12","key":"3012_CR64","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/mcb.01748-12","volume":"33","author":"A Lau","year":"2013","unstructured":"Lau A, et al. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner, (in eng). Mol Cell Biol. 2013;33(12):2436\u201346. https:\/\/doi.org\/10.1128\/mcb.01748-12.","journal-title":"Mol Cell Biol"},{"issue":"27","key":"3012_CR65","doi-asserted-by":"publisher","first-page":"16114","DOI":"10.1074\/jbc.270.27.16114","volume":"270","author":"CN Palmer","year":"1995","unstructured":"Palmer CN, Hsu MH, Griffin HJ, Johnson EF. \u201cNovel sequence determinants in peroxisome proliferator signaling,\u201d (in eng). J Biol Chem. 1995;270(27):16114\u201321. https:\/\/doi.org\/10.1074\/jbc.270.27.16114.","journal-title":"J Biol Chem"},{"key":"3012_CR66","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1007\/s11064-021-03402-1","volume":"46","author":"A Mannan","year":"2021","unstructured":"Mannan A, Garg N, Singh TG, Kang HK. Peroxisome proliferator-activated receptor-gamma (PPAR-\u0263): molecular effects and its importance as a novel therapeutic target for cerebral ischemic injury. Neurochem Res. 2021;46:2800\u201331.https:\/\/doi.org\/10.1007\/s11064-021-03402-1","journal-title":"Neurochem Res"},{"key":"3012_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/641087","volume":"2012","author":"S Polvani","year":"2012","unstructured":"Polvani S, Tarocchi M, Galli A. PPAR\u03b3 and oxidative stress: Con(\u03b2) catenating NRF2 and FOXO, (in eng). PPAR Res. 2012;2012:641087. https:\/\/doi.org\/10.1155\/2012\/641087.","journal-title":"PPAR Res"},{"key":"3012_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110373","volume":"129","author":"V Sharma","year":"2020","unstructured":"Sharma V, Kaur A, Singh TG. Counteracting role of nuclear factor erythroid 2-related factor 2 pathway in Alzheimer\u2019s disease. Biomed Pharmacother. 2020;129:110373. https:\/\/doi.org\/10.1016\/j.biopha.2020.110373.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3012_CR69","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.Cir-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM. NF-\u03baB, an active player in human cancers, (in eng). Cancer Immunol Res. 2014;2(9):823\u201330. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0112.","journal-title":"Cancer Immunol Res"},{"key":"3012_CR70","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation, (in eng). Signal Transduct Target Ther. 2017;2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23.","journal-title":"Signal Transduct Target Ther"},{"issue":"26","key":"3012_CR71","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-\u03baB and underlies its chemo-resistance. Blood. 2012;120(26):5188\u201398.https:\/\/doi.org\/10.1182\/blood-2012-04-422121","journal-title":"Blood"},{"key":"3012_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01565-3","volume":"39","author":"JE Jang","year":"2020","unstructured":"Jang JE, et al. PERK\/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. J Exp Clin Cancer Res. 2020;39:1\u201314.https:\/\/doi.org\/10.1186\/s13046-020-01565-3","journal-title":"J Exp Clin Cancer Res"},{"issue":"26","key":"3012_CR73","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"SA Rushworth","year":"2012","unstructured":"Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-\u03baB and underlies its chemo-resistance, (in eng). Blood. 2012;120(26):5188\u201398. https:\/\/doi.org\/10.1182\/blood-2012-04-422121.","journal-title":"Blood"},{"issue":"5","key":"3012_CR74","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/0008-5472.Can-10-3018","volume":"71","author":"SA Rushworth","year":"2011","unstructured":"Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors, (in eng). Cancer Res. 2011;71(5):1999\u20132009. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-3018.","journal-title":"Cancer Res"},{"issue":"4","key":"3012_CR75","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","volume":"135","author":"T Shibata","year":"2008","unstructured":"Shibata T, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer, (in eng). Gastroenterology. 2008;135(4):1358\u201368. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.082.","journal-title":"Gastroenterology"},{"issue":"3","key":"3012_CR76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cllc.2011.03.012","volume":"12","author":"H Yang","year":"2011","unstructured":"Yang H, et al. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer. 2011;12(3):166\u201371. https:\/\/doi.org\/10.1016\/j.cllc.2011.03.012.","journal-title":"Clin Lung Cancer"},{"issue":"13","key":"3012_CR77","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1158\/0008-5472.Can-10-0713","volume":"70","author":"T Jiang","year":"2010","unstructured":"Jiang T, et al. High levels of Nrf2 determine chemoresistance in type II endometrial cancer, (in eng). Cancer Res. 2010;70(13):5486\u201396. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-0713.","journal-title":"Cancer Res"},{"issue":"9","key":"3012_CR78","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.7314\/apjcp.2013.14.9.5231","volume":"14","author":"XF Hu","year":"2013","unstructured":"Hu XF, et al. Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer, (in eng). Asian Pac J Cancer Prev. 2013;14(9):5231\u20135. https:\/\/doi.org\/10.7314\/apjcp.2013.14.9.5231.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"3012_CR79","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/PAT.0b013e328359d54b","volume":"44","author":"JY Park","year":"2012","unstructured":"Park JY, Kim YW, Park YK. Nrf2 expression is associated with poor outcome in osteosarcoma, (in eng). Pathology. 2012;44(7):617\u201321. https:\/\/doi.org\/10.1097\/PAT.0b013e328359d54b.","journal-title":"Pathology"},{"issue":"7","key":"3012_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24561","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Jiang Pj, Lv My, Zhao Yh, Cui J, Chen J. OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells. J Clin Lab Anal. 2022;36(7):e24561.https:\/\/doi.org\/10.1002\/jcla.24561","journal-title":"J Clin Lab Anal"},{"issue":"27","key":"3012_CR81","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2217\/fon-2020-1155","volume":"17","author":"K Zoraiz","year":"2021","unstructured":"Zoraiz K, Attique M, Shahbaz S, Ahmed MW, Kayani MA, Mahjabeen I. Deregulation of mitochondrial sirtuins and OGG1-2a acts as a prognostic and diagnostic biomarker in leukemia. Future Oncol. 2021;17(27):3561\u201377.https:\/\/doi.org\/10.2217\/fon-2020-1155","journal-title":"Future Oncol"},{"key":"3012_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102798","author":"Q Shang","year":"2023","unstructured":"Shang Q, et al. Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine. J Biol Chem. 2023. https:\/\/doi.org\/10.1016\/j.jbc.2022.102798.","journal-title":"J Biol Chem"},{"issue":"1","key":"3012_CR83","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1038\/s41598-021-82917-7","volume":"11","author":"JM Baquero","year":"2021","unstructured":"Baquero JM, et al. Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects. Sci Rep. 2021;11(1):3490.https:\/\/doi.org\/10.1038\/s41598-021-82917-7","journal-title":"Sci Rep"},{"key":"3012_CR84","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fonc.2020.01575","volume":"10","author":"CL Starcher","year":"2020","unstructured":"Starcher CL, et al. Targeting base excision repair in cancer: NQO1-bioactivatable drugs improve tumor selectivity and reduce treatment toxicity through radiosensitization of human cancer, (in eng). Front Oncol. 2020;10:1575. https:\/\/doi.org\/10.3389\/fonc.2020.01575.","journal-title":"Front Oncol"},{"issue":"2","key":"3012_CR85","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88.https:\/\/doi.org\/10.1038\/s41419-020-2298-2","journal-title":"Cell Death Dis"},{"issue":"11","key":"3012_CR86","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41419-021-04307-1","volume":"12","author":"H Dong","year":"2021","unstructured":"Dong H, et al. Nrf2 attenuates ferroptosis-mediated IIR-ALI by modulating TERT and SLC7A11. Cell Death Dis. 2021;12(11):1027.https:\/\/doi.org\/10.1038\/s41419-021-04307-1","journal-title":"Cell Death Dis"},{"key":"3012_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091291","author":"L Valgimigli","year":"2023","unstructured":"Valgimigli L. Lipid Peroxidation and Antioxidant Protection, (in eng). Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13091291.","journal-title":"Biomolecules"},{"issue":"1","key":"3012_CR88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41419-020-03297-w","volume":"12","author":"F Thayyullathil","year":"2021","unstructured":"Thayyullathil F, et al. Acid sphingomyelinase-dependent autophagic degradation of GPX4 is critical for the execution of ferroptosis, (in eng). Cell Death Dis. 2021;12(1):26. https:\/\/doi.org\/10.1038\/s41419-020-03297-w.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3012_CR89","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","volume":"11","author":"J Winter","year":"2009","unstructured":"Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microrna biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228\u201334.https:\/\/doi.org\/10.1038\/ncb0309-228","journal-title":"Nat Cell Biol"},{"issue":"10","key":"3012_CR90","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704\u201314.https:\/\/doi.org\/10.1038\/nrg2634","journal-title":"Nat Rev Genet"},{"issue":"1","key":"3012_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03430-1","volume":"24","author":"R Panahizadeh","year":"2024","unstructured":"Panahizadeh R, et al. The interplay between microRNAs and Nrf2 signaling in human cancers. Cancer Cell Int. 2024;24(1):234.https:\/\/doi.org\/10.1186\/s12935-024-03430-1","journal-title":"Cancer Cell Int"},{"issue":"10","key":"3012_CR92","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges, (in eng). Nat Rev Drug Discov. 2010;9(10):775\u201389. https:\/\/doi.org\/10.1038\/nrd3179.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3012_CR93","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/jcb.24038","volume":"113","author":"RS Redis","year":"2012","unstructured":"Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Non-coding RNAs as theranostics in human cancers. J Cell Biochem. 2012;113(5):1451\u20139.https:\/\/doi.org\/10.1002\/jcb.24038","journal-title":"J Cell Biochem"},{"issue":"4","key":"3012_CR94","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/cdd.2014.152","volume":"22","author":"N Shah","year":"2015","unstructured":"Shah N, Zaitseva L, Bowles K, MacEwan D, Rushworth S. NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death Differ. 2015;22(4):654\u201364.10.1038\/cdd.2014.152","journal-title":"Cell Death Differ"},{"issue":"4","key":"3012_CR95","first-page":"679","volume":"63","author":"X Sun","year":"2017","unstructured":"Sun X, Liu D, Xue Y, Hu X. Enforced miR-144-3p expression as a non-invasive biomarker for the acute myeloid leukemia patients mainly by targeting NRF2. Clin Lab. 2017;63(4):679\u201387.10.7754\/Clin.Lab.2016.161116","journal-title":"Clin Lab"},{"issue":"1","key":"3012_CR96","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s42003-024-06243-0","volume":"7","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Activation of Nrf2\/HO-1 signaling pathway exacerbates cholestatic liver injury. Commun Biol. 2024;7(1):621.https:\/\/doi.org\/10.1038\/s42003-024-06243-0","journal-title":"Commun Biol"},{"issue":"2","key":"3012_CR97","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-022-06565-9","volume":"193","author":"Q Tan","year":"2022","unstructured":"Tan Q, Qin Q, Huang Z, Lian B, Mo Q, Wei C. Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2022;193(2):393\u2013403.\u00a0 DOI: 10.1007\/s10549-022-06565-9","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"3012_CR98","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.leukres.2015.02.009","volume":"39","author":"X Lin","year":"2015","unstructured":"Lin X, et al. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK\/c-JUN signaling pathway. Leuk Res. 2015;39(5):544\u201352.10.1016\/j.leukres.2015.02.009","journal-title":"Leuk Res"},{"issue":"7","key":"3012_CR99","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1179\/1607845414Y.0000000212","volume":"20","author":"N Zhe","year":"2015","unstructured":"Zhe N, et al. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. Hematology. 2015;20(7):384\u201391.10.1179\/1607845414Y.0000000212","journal-title":"Hematology"},{"issue":"1","key":"3012_CR100","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-020-03331-x","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu P, Ma D, Wang P, Pan C, Fang Q, Wang J. Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2. Cell Death Dis. 2021;12(1):20.https:\/\/doi.org\/10.1038\/s41419-020-03331-x","journal-title":"Cell Death Dis"},{"key":"3012_CR101","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s42255-019-0043-x","volume":"1","author":"L Chen","year":"2019","unstructured":"Chen L, et al. NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism, (in eng). Nat Metab. 2019;1:404\u201315.https:\/\/doi.org\/10.1038\/s42255-019-0043-x","journal-title":"Nat Metab"},{"issue":"8","key":"3012_CR102","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s13238-014-0082-8","volume":"5","author":"P Jiang","year":"2014","unstructured":"Jiang P, Du W, Wu M. Regulation of the pentose phosphate pathway in cancer, (in eng). Protein Cell. 2014;5(8):592\u2013602. https:\/\/doi.org\/10.1007\/s13238-014-0082-8.","journal-title":"Protein Cell"},{"key":"3012_CR103","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1007\/s13277-015-4428-5","volume":"37","author":"Y Chen","year":"2016","unstructured":"Chen Y, et al. Inhibition of pentose phosphate pathway suppresses acute myelogenous leukemia. Tumor Biol. 2016;37:6027\u201334.https:\/\/doi.org\/10.1007\/s13277-015-4428-5","journal-title":"Tumor Biol"},{"issue":"8","key":"3012_CR104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra KC, Hay N. The pentose phosphate pathway and cancer, (in eng). Trends Biochem Sci. 2014;39(8):347\u201354. https:\/\/doi.org\/10.1016\/j.tibs.2014.06.005.","journal-title":"Trends Biochem Sci"},{"issue":"11","key":"3012_CR105","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.7150\/thno.53417","volume":"11","author":"YC Tang","year":"2021","unstructured":"Tang YC, et al. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation, (in eng). Theranostics. 2021;11(11):5232\u201347. https:\/\/doi.org\/10.7150\/thno.53417.","journal-title":"Theranostics"},{"key":"3012_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00242-z","volume":"8","author":"NM Kaweme","year":"2020","unstructured":"Kaweme NM, Zhou S, Changwe GJ, Zhou F. The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications. Biomarker Research. 2020;8:1\u201312https:\/\/doi.org\/10.1186\/s40364-020-00242-z.","journal-title":"Biomarker Research"},{"issue":"11","key":"3012_CR107","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41375-019-0456-2","volume":"33","author":"Y Dong","year":"2019","unstructured":"Dong Y, et al. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Leukemia. 2019;33(11):2585\u201398.10.1038\/s41375-019-0456-2","journal-title":"Leukemia"},{"issue":"3","key":"3012_CR108","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2007.02.003","volume":"62","author":"SD de Jonge-Peeters","year":"2007","unstructured":"de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 2007;62(3):214\u201326.10.1016\/j.critrevonc.2007.02.003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"3012_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S, et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2, (in eng). PLoS ONE. 2017;12(5):e0177227. https:\/\/doi.org\/10.1371\/journal.pone.0177227.","journal-title":"PLoS ONE"},{"issue":"1","key":"3012_CR110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41420-024-01800-2","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway. Cell Death Discov. 2024;10(1):35.https:\/\/doi.org\/10.1038\/s41420-024-01800-2","journal-title":"Cell Death Discov"},{"issue":"4","key":"3012_CR111","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41416-022-02074-0","volume":"128","author":"L Wang","year":"2023","unstructured":"Wang L, et al. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RAR\u03b1-Nrf2 complex, (in eng). Br J Cancer. 2023;128(4):691\u2013701. https:\/\/doi.org\/10.1038\/s41416-022-02074-0.","journal-title":"Br J Cancer"},{"issue":"6","key":"3012_CR112","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/01635581.2019.1578387","volume":"71","author":"Y Li","year":"2019","unstructured":"Li Y, et al. Involvement of the PI3K\/Akt\/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60\/ADR cells, (in eng). Nutr Cancer. 2019;71(6):1007\u201318. https:\/\/doi.org\/10.1080\/01635581.2019.1578387.","journal-title":"Nutr Cancer"},{"issue":"42","key":"3012_CR113","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1074\/jbc.M116.750653","volume":"291","author":"S Pei","year":"2016","unstructured":"Pei S, et al. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells, (in eng). J Biol Chem. 2016;291(42):21984\u20132000. https:\/\/doi.org\/10.1074\/jbc.M116.750653.","journal-title":"J Biol Chem"},{"key":"3012_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.176","author":"B Xu","year":"2017","unstructured":"Xu B, Wang S, Li R, Chen K, He L, Deng M, et al. Disulfiram\/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-\u03baB and Nrf2. Cell Death Dis. 2017. https:\/\/doi.org\/10.1038\/cddis.2017.176.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3012_CR115","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41416-021-01570-z","volume":"126","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, et al. Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing. British J Cancer. 2022;126(2):275\u201386. https:\/\/doi.org\/10.1038\/s41416-021-01570-z.","journal-title":"British J Cancer"},{"issue":"6","key":"3012_CR116","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00277-024-05742-8","volume":"103","author":"DZP Jebanesan","year":"2024","unstructured":"Jebanesan DZP, et al. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated acute myeloid leukemia. Ann Hematol. 2024;103(6):1919\u201329. https:\/\/doi.org\/10.1007\/s00277-024-05742-8.","journal-title":"Ann Hematol"},{"issue":"1","key":"3012_CR117","doi-asserted-by":"publisher","first-page":"233","DOI":"10.20517\/cdr.2021.122","volume":"5","author":"L Cuesta-Casanovas","year":"2022","unstructured":"Cuesta-Casanovas L, Delgado-Mart\u00ednez J, Cornet-Masana JM, Carb\u00f3 JM, Cl\u00e9ment-Demange L, Risue\u00f1o RM. Lysosome-mediated chemoresistance in acute myeloid leukemia, (in eng). Cancer Drug Resist. 2022;5(1):233\u201344. https:\/\/doi.org\/10.20517\/cdr.2021.122.","journal-title":"Cancer Drug Resist"},{"issue":"9","key":"3012_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6806","volume":"13","author":"C Fan","year":"2024","unstructured":"Fan C, Yang X, Yan L, Shi Z. Oxidative stress is two-sided in the treatment of acute myeloid leukemia. Cancer Med. 2024;13(9):e6806.10.1002\/cam4.6806","journal-title":"Cancer Med"},{"key":"3012_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11:104.10.1038\/s41408-021-00495-3","journal-title":"Blood Cancer J"},{"issue":"22","key":"3012_CR120","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1182\/blood.2021013182","volume":"138","author":"R Bhatia","year":"2021","unstructured":"Bhatia R. Fattening up FLT3-ITD for the kill. Blood. 2021;138(22):2158\u20139.10.1182\/blood.2021013182","journal-title":"Blood"},{"issue":"5","key":"3012_CR121","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104.","journal-title":"Blood Cancer J"},{"issue":"3","key":"3012_CR122","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620714532123","volume":"5","author":"SA Wander","year":"2014","unstructured":"Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond, (in eng). Ther Adv Hematol. 2014;5(3):65\u201377. https:\/\/doi.org\/10.1177\/2040620714532123.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"3012_CR123","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682\u201396.10.1038\/s41375-019-0694-3","journal-title":"Leukemia"},{"issue":"no. 6","key":"3012_CR124","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105(6):1507. 10.3324\/haematol.2019.243410","journal-title":"Haematologica"},{"key":"3012_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11040717","author":"S Kannan","year":"2022","unstructured":"Kannan S, et al. Targeting the NRF2\/HO-1 antioxidant pathway in FLT3-ITD-positive AML enhances therapy efficacy, (in eng). Antioxidants (Basel). 2022. https:\/\/doi.org\/10.3390\/antiox11040717.","journal-title":"Antioxidants (Basel)"},{"issue":"6","key":"3012_CR126","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00277-024-05742-8","volume":"103","author":"DZP Jebanesan","year":"2024","unstructured":"Jebanesan DZP, et al. Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated acute myeloid leukemia. Ann Hematol. 2024;103(6):1919\u201329.\u00a010.1007\/s00277-024-05742-8.","journal-title":"Ann Hematol"},{"issue":"7","key":"3012_CR127","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389.https:\/\/doi.org\/10.1038\/s41375-021-01218-0","journal-title":"Leukemia"},{"issue":"12","key":"3012_CR128","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511\u201321. https:\/\/doi.org\/10.1002\/ajh.25978.","journal-title":"Am J Hematol"},{"issue":"20","key":"3012_CR129","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.1158\/1078-0432.Ccr-17-1201","volume":"23","author":"X Li","year":"2017","unstructured":"Li X, et al. Increased IFN\u03b3(+) T cells are responsible for the clinical responses of low-dose DNA-demethylating agent decitabine antitumor therapy, (in eng). Clin Cancer Res. 2017;23(20):6031\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-1201.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3012_CR130","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1002\/jcp.28091","volume":"234","author":"LXT Nguyen","year":"2019","unstructured":"Nguyen LXT, et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML, (in eng). J Cell Physiol. 2019;234(8):14040\u20139. https:\/\/doi.org\/10.1002\/jcp.28091.","journal-title":"J Cell Physiol"},{"issue":"11","key":"3012_CR131","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","volume":"11","author":"A Singh","year":"2016","unstructured":"Singh A, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors, (in eng). ACS Chem Biol. 2016;11(11):3214\u201325. https:\/\/doi.org\/10.1021\/acschembio.6b00651.","journal-title":"ACS Chem Biol"},{"key":"3012_CR132","doi-asserted-by":"publisher","DOI":"10.1007\/s11094-025-03301-7","author":"H Yang","year":"2025","unstructured":"Yang H, Zheng W, Lin H, Huang H. ML385 suppresses hypoxia-induced drug resistance and cancer stemness of breast cancer cells by blocking the Nrf2\/HO-1 pathway. Pharm Chem J. 2025. https:\/\/doi.org\/10.1007\/s11094-025-03301-7.","journal-title":"Pharm Chem J"},{"issue":"1","key":"3012_CR133","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-023-00411-4","volume":"12","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis, (in eng). Exp Hematol Oncol. 2023;12(1):47. https:\/\/doi.org\/10.1186\/s40164-023-00411-4.","journal-title":"Exp Hematol Oncol"},{"key":"3012_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17070997","author":"X Sun","year":"2016","unstructured":"Sun X, Wang Q, Wang Y, Du L, Xu C, Liu Q. Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17070997.","journal-title":"Int J Mol Sci"},{"key":"3012_CR135","doi-asserted-by":"publisher","first-page":"444.4","DOI":"10.1096\/fasebj.30.1_supplement.444.4","volume":"30","author":"Y Li","year":"2016","unstructured":"Li Y, Zhou Y, Ni HM, Zhong H, Ding WX. Nrf2 but not autophagy activation is associated with resistance to EGFR inhibitor-induced lung tumor cell apoptosis. FASEB J. 2016;30:444.4-444.4.https:\/\/doi.org\/10.1096\/fasebj.30.1_supplement.444.4","journal-title":"FASEB J"},{"issue":"10","key":"3012_CR136","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.7150\/ijbs.82401","volume":"19","author":"J Zhang","year":"2023","unstructured":"Zhang J, Xu HX, Zhu JQ, Dou YX, Xian YF, Lin ZX. Natural Nrf2 inhibitors: a review of their potential for cancer treatment. Int J Biol Sci. 2023;19(10):3029\u201341. https:\/\/doi.org\/10.7150\/ijbs.82401.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"3012_CR137","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/156800908786241050","volume":"8","author":"Y Lin","year":"2008","unstructured":"Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008;8(7):634\u201346. https:\/\/doi.org\/10.2174\/156800908786241050.","journal-title":"Curr Cancer Drug Targets"},{"key":"3012_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153437","volume":"81","author":"HT Wu","year":"2021","unstructured":"Wu HT, et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT\/mTOR signaling pathway, (in eng). Phytomedicine. 2021;81:153437. https:\/\/doi.org\/10.1016\/j.phymed.2020.153437.","journal-title":"Phytomedicine"},{"issue":"2","key":"3012_CR139","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/01635581.2021.1903947","volume":"74","author":"HS Yoo","year":"2022","unstructured":"Yoo HS, Won SB, Kwon YH. Luteolin induces apoptosis and autophagy in HCT116 colon cancer cells via p53-dependent pathway, (in eng). Nutr Cancer. 2022;74(2):677\u201386. https:\/\/doi.org\/10.1080\/01635581.2021.1903947.","journal-title":"Nutr Cancer"},{"issue":"11","key":"3012_CR140","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","volume":"50","author":"X Tang","year":"2011","unstructured":"Tang X, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011;50(11):1599\u2013609.\u00a010.1016\/j.freeradbiomed.2011.03.008","journal-title":"Free Radic Biol Med"},{"key":"3012_CR141","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S509007","author":"W Wang","year":"2025","unstructured":"Wang W, et al. Mechanism of a novel complex: zinc oxide nanoparticles-luteolin to promote ferroptosis in human acute myeloid leukemia cells in vitro. Int J Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/IJN.S509007.","journal-title":"Int J Nanomedicine"},{"key":"3012_CR142","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.biopha.2017.04.003","volume":"90","author":"C Xi","year":"2017","unstructured":"Xi C, Peng S, Wu Z, Zhou Q, Zhou J. Toxicity of triptolide and the molecular mechanisms involved. Biomed Pharmacother. 2017;90:531\u201341.\u00a010.1016\/j.biopha.2017.04.003","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"3012_CR143","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3727\/096504013X13657689382932","volume":"20","author":"J-X Ma","year":"2013","unstructured":"Ma J-X, Sun Y-L, Wang Y-Q, Wu H-Y, Jin J, Yu X-F. Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res. 2013;20(8):359\u201368.\u00a010.3727\/096504013X13657689382932","journal-title":"Oncol Res"},{"issue":"12","key":"3012_CR144","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.exphem.2008.08.002","volume":"36","author":"A Pigneux","year":"2008","unstructured":"Pigneux A, et al. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells, (in eng). Exp Hematol. 2008;36(12):1648\u201359. https:\/\/doi.org\/10.1016\/j.exphem.2008.08.002.","journal-title":"Exp Hematol"},{"issue":"5","key":"3012_CR145","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.athoracsur.2015.05.074","volume":"100","author":"TA Reno","year":"2015","unstructured":"Reno TA, Kim JY, Raz DJ. Triptolide inhibits lung cancer cell migration, invasion, and metastasis. Ann Thorac Surg. 2015;100(5):1817\u201325.10.1016\/j.athoracsur.2015.05.074","journal-title":"Ann Thorac Surg"},{"key":"3012_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2018.09.004","volume":"358","author":"J Zhu","year":"2018","unstructured":"Zhu J, et al. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity. Toxicol Appl Pharmacol. 2018;358:1\u20139.10.1016\/j.taap.2018.09.004","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11\u201312","key":"3012_CR147","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/10715762.2018.1489132","volume":"52","author":"J Lee","year":"2018","unstructured":"Lee J, Kang J-S, Nam LB, Yoo O-K, Keum Y-S. Suppression of NRF2\/ARE by convallatoxin sensitises A549 cells to 5-FU-mediated apoptosis. Free Radic Res. 2018;52(11\u201312):1416\u201323.10.1080\/10715762.2018.1489132","journal-title":"Free Radic Res"},{"issue":"6","key":"3012_CR148","first-page":"647","volume":"8","author":"MA Borg","year":"2017","unstructured":"Borg MA, Clemmons A. Venetoclax: a novel treatment for patients with del(17p) chronic lymphocytic leukemia, (in eng). J Adv Pract Oncol. 2017;8(6):647\u201352.","journal-title":"J Adv Pract Oncol"},{"key":"3012_CR149","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S. \u201cVenetoclax: evidence to date and clinical potential,\u201d (in eng). Drugs Context. 2019;8:212574. https:\/\/doi.org\/10.7573\/dic.212574.","journal-title":"Drugs Context"},{"issue":"22","key":"3012_CR150","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma, (in eng). Blood. 2017;130(22):2401\u20139. https:\/\/doi.org\/10.1182\/blood-2017-06-788786.","journal-title":"Blood"},{"issue":"1","key":"3012_CR151","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-025-01264-2","volume":"15","author":"A Bolarinwa","year":"2025","unstructured":"Bolarinwa A, et al. Venetoclax-based treatment combinations in relapsed\/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes, (in eng). Blood Cancer J. 2025;15(1):57. https:\/\/doi.org\/10.1038\/s41408-025-01264-2.","journal-title":"Blood Cancer J"},{"issue":"10","key":"3012_CR152","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.Cd-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, et al. Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0313.","journal-title":"Cancer Discov"},{"issue":"24","key":"3012_CR153","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1, (in eng). Blood. 2022;140(24):2594\u2013610. https:\/\/doi.org\/10.1182\/blood.2021014241.","journal-title":"Blood"},{"issue":"3","key":"3012_CR154","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","volume":"87","author":"CE Carow","year":"1996","unstructured":"Carow CE, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias, (in eng). Blood. 1996;87(3):1089\u201396.","journal-title":"Blood"},{"issue":"5","key":"3012_CR155","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia, (in eng). Blood. 2002;100(5):1532\u201342. https:\/\/doi.org\/10.1182\/blood-2002-02-0492.","journal-title":"Blood"},{"issue":"4","key":"3012_CR156","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/antiox11040717","volume":"11","author":"S Kannan","year":"2022","unstructured":"Kannan S, et al. Targeting the NRF2\/HO-1 antioxidant pathway in FLT3-ITD-positive AML enhances therapy efficacy. Antioxidants. 2022;11(4):717.10.3390\/antiox11040717","journal-title":"Antioxidants"},{"issue":"11","key":"3012_CR157","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. \u201cCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials,\u201d (in eng). Cancer. 2003;97(11):2869\u201379. https:\/\/doi.org\/10.1002\/cncr.11407.","journal-title":"Cancer"},{"key":"3012_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3012_CR159","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/antiox10030349","volume":"10","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, et al. Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery. Antioxidants. 2021;10(3):349.","journal-title":"Antioxidants"},{"issue":"19","key":"3012_CR160","doi-asserted-by":"publisher","first-page":"10257","DOI":"10.3390\/ijms251910257","volume":"25","author":"M Juszczak","year":"2024","unstructured":"Juszczak M, Tokarz P, Wo\u017aniak K. Potential of NRF2 inhibitors\u2014retinoic acid, K67, and ML-385\u2014in overcoming doxorubicin resistance in promyelocytic leukemia cells. Int J Mol Sci. 2024;25(19):10257.\u00a010.3390\/ijms251910257","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3012_CR161","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41408-018-0087-2","volume":"8","author":"I Laverdi\u00e8re","year":"2018","unstructured":"Laverdi\u00e8re I, et al. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia. Blood Cancer J. 2018;8(6):52. https:\/\/doi.org\/10.1038\/s41408-018-0087-2.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3012_CR162","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","volume":"25","author":"DA Russler-Germain","year":"2014","unstructured":"Russler-Germain DA, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers, (in eng). Cancer Cell. 2014;25(4):442\u201354. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.010.","journal-title":"Cancer Cell"},{"issue":"45","key":"3012_CR163","doi-asserted-by":"publisher","first-page":"16966","DOI":"10.1074\/jbc.RA119.010126","volume":"294","author":"TV Nguyen","year":"2019","unstructured":"Nguyen TV, et al. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity, (in eng). J Biol Chem. 2019;294(45):16966\u201377. https:\/\/doi.org\/10.1074\/jbc.RA119.010126.","journal-title":"J Biol Chem"},{"key":"3012_CR164","doi-asserted-by":"publisher","first-page":"10924","DOI":"10.1038\/ncomms10924","volume":"7","author":"J Koya","year":"2016","unstructured":"Koya J, et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun. 2016;7:10924. https:\/\/doi.org\/10.1038\/ncomms10924.","journal-title":"Nat Commun"},{"issue":"11","key":"3012_CR165","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.neo.2018.08.013","volume":"20","author":"R Bera","year":"2018","unstructured":"Bera R, Chiu MC, Huang YJ, Liang DC, Lee YS, Shih LY. Genetic and epigenetic perturbations by DNMT3A-R882 mutants impaired apoptosis through augmentation of PRDX2 in myeloid leukemia cells. Neoplasia. 2018;20(11):1106\u201320. https:\/\/doi.org\/10.1016\/j.neo.2018.08.013.","journal-title":"Neoplasia"},{"key":"3012_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653030","volume":"12","author":"Y Que","year":"2021","unstructured":"Que Y, et al. Study on the immune escape mechanism of acute myeloid leukemia with DNMT3A mutation, (in eng). Front Immunol. 2021;12:653030. https:\/\/doi.org\/10.3389\/fimmu.2021.653030.","journal-title":"Front Immunol"},{"issue":"1","key":"3012_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00978-1","volume":"20","author":"X Chu","year":"2022","unstructured":"Chu X, et al. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2\/NQO1 pathway. Cell Commun Signal. 2022;20(1):168.\u00a010.1186\/s12964-022-00978-1","journal-title":"Cell Commun Signal"},{"issue":"5","key":"3012_CR168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath S, Rajamani BM, Musheer Aalam SM, Abraham A, Varatharajan S, Krishnamurthy P, et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS ONE. 2017;12(5):e0177227. https:\/\/doi.org\/10.1371\/journal.pone.0177227.","journal-title":"PLoS ONE"},{"key":"3012_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111652","volume":"142","author":"C Cheng","year":"2021","unstructured":"Cheng C, et al. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother. 2021;142:111652.\u00a0https:\/\/doi.org\/10.1016\/j.biopha.2021.111652","journal-title":"Biomed Pharmacother"},{"key":"3012_CR170","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.freeradbiomed.2023.07.008","volume":"207","author":"PP Praharaj","year":"2023","unstructured":"Praharaj PP, Singh A, Patra S, Bhutia SK. Co-targeting autophagy and NRF2 signaling triggers mitochondrial superoxide to sensitize oral cancer stem cells for cisplatin-induced apoptosis. Free Radic Biol Med. 2023;207:72\u201388.\u00a0 10.1016\/j.freeradbiomed.2023.07.008","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3012_CR171","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/mmr.2022.12904","volume":"27","author":"X Wu","year":"2022","unstructured":"Wu X, Chen S, Huang K, Lin G. Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. Mol Med Rep. 2022;27(1):17.\u00a0 10.3892\/mmr.2022.12904","journal-title":"Mol Med Rep"},{"key":"3012_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108700","volume":"697","author":"C Fouzder","year":"2021","unstructured":"Fouzder C, Mukhuty A, Kundu R. Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells. Arch Biochem Biophys. 2021;697:108700.\u00a010.1016\/j.abb.2020.108700","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"3012_CR173","doi-asserted-by":"publisher","first-page":"398","DOI":"10.22037\/ijpr.2019.14907.12738","volume":"20","author":"A Jalali","year":"2021","unstructured":"Jalali A, Mahmoudi S, Harchegani AL, Mohammadiasl J, Ahmadzadeh A. Evaluation of Nrf2, Keap1 and apoptotic pathway genes expression in acute myeloid leukemia patients. Iranian J Pharm Res. 2021;20(1):398. https:\/\/doi.org\/10.22037\/ijpr.2019.14907.12738.","journal-title":"Iranian J Pharm Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03012-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:02:33Z","timestamp":1758096153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03012-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":173,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03012-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"460"}}